Immunizing compositions and methods of use

The current invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and instead, lipopolysaccharide at a concentration of no more than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and ways of using such compositions, including inducing the production of antibody in a creature.


To view all patent detail click here





The financial impact of infectious diseases in food animal production is well appreciated. Infectious diseases reduce gains, increase production costs, and endanger the overall wholesomeness of their food products, in addition to effect theperformance, health and welfare of the animal. This disease status can reduce the yield and quality of milk resulting in great financial loss to the dairymen. Sometimes, infectious microbial diseases can lead to morbidity and mortality of newborn,young (e.g., replacement stock) or adult animals.

The agricultural sector currently relies on antibiotic treatment and vaccines to decrease losses caused by clinical and subclinical infectious diseases, such as autoimmune disease, respiratory disease, and systemic illness. But, forsome states, antibiotics are unsuccessful, can prolong the illness, or induce a carrier condition. Vaccines have often proven to be an effective way of controlling infectious diseases, however, worries relating to adverse impacts or lack of protectionagainst several microbes are a major drawback to current vaccines. For example, vaccines can be found which contain one or more immunogens from an individual genus, species, or strain of microbe; however, few, if any, supply cross-protectionor stimulate broad-based immunity from several strains, species or even genera of microbe.

Vaccines containing molecules obtained from g negative microbes typically include contaminating amounts of lipopolysaccharide (LPS), a component of the outer membrane of most gram negative microbes. The presence of LPS in an injectableproduct can result in an inflammatory reaction at the website of injection that can result in swelling, tenderness and often the creation of a granuloma at the website of injection. In rare cases, it can result in anaphylactic shock and death. Thisnon-specific inflammatory reaction in a manufacturing creature can result in significant financial losses due to raising the likelihood of disease by increasing the level of anxiety of the creature, and adversely effecting performance characteristics of theanimal. Additionally, the creation of a granuloma at the injection site can result in significant financial losses due to blemishes and scarring of the carcass that are often trimmed during processing resulting in the reduction of product and down grading ofthe carcass. While methods for elimination of LPS from compositions exist, this can be not feasible for use with vaccines that include whole cells. Moreover, due to the high costs of eliminating LPS out of solutions, it is typically not efficiently practicalto remove LPS from vaccines for use in non-human animals.

IP reviewed by Plant-Grow agriculture technology news